Content of the article
TORONTO, Oct. 05, 2022 (GLOBE NEWSWIRE) — Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical-stage company focused on developing of innovative technologies and new therapeutics aimed at organ inflammation, welcomed Mr. Farris Smith of Novo Nordisk Canada Inc as strategic advisor for general corporate activity and business development of the company’s drug candidates.
Farris Smith began his career at AP Moller in 2001 and joined Novo Nordisk in 2003 as Head of Finance and Human Resources for the Arab Gulf countries and has since held finance and operational roles in increasing size and complexity throughout the global Novo Nordisk organization. From 2010 to 2012, Farris led the Finance and Business Development organization for the Latin American Region and in 2013 moved to France as CFO of France and BeLux. In 2016, he moved into his current role as CFO for Novo Nordisk’s Canadian business and has supported the organization through a period of significant development. In 2022, Farris was recognized as CFO of the Year, an award that recognizes leadership excellence across Novo Nordisk. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark.
Content of the article
“Arch Biopartners has demonstrated the ability and commitment to bring forward innovative drug candidates,” said Farris Smith. “I am excited to work with this dedicated and talented team to achieve their goals and bring improved treatments to people in need.”
“On behalf of the Arch team, we look forward to working with Farris to help guide Arch as the company grows in pursuit of drug approval and commercial opportunities,” said Richard Muruve, CEO of Arch Biopartners.
About Arch Biopartners
Arch Biopartners Inc. is a clinical-stage company focused on the development of innovative technologies that have the potential to have a significant medical or commercial impact. Arch Biopartners is developing a series of new drug candidates that inhibit inflammation in the lungs, liver and kidneys via the dipeptidase-1 (DPEP-1) pathway, relevant to multiple medical indications.
Content of the article
For more information about Arch Biopartners, its technologies and other public filings Arch has filed on SEDAR, visit www.archbiopartners.com
The Company has 62,330,292 common shares outstanding.
For more information, please contact:
Richard Muruve
CEO
Arch Biopartners Inc.
1 647 428 7031
Send a message or sign up for email alerts on the company’s website using this link: www.archbiopartners.com/contact-us
Forward-looking statements
This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements within the meaning of applicable securities laws, which are based on the beliefs and assumptions of Arch Biopartners’ management and information available currently by Arch Biopartners. ‘ management. All statements, other than statements of historical fact, in this press release are considered forward-looking statements that involve various risks and uncertainties, including, without limitation, statements about the Company’s future plans and objectives. No assurance can be given that these statements are accurate. Actual results and future events could differ materially from those anticipated in these statements. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “could,” “might,” “outlook,” “believe,” “plan,” “anticipate,” “expect.” . and “estimate”, or the negatives of those terms, or variations thereof. Forward-looking statements contained in this press release include, but are not limited to, statements regarding the potential efficacy and safety of LSALT peptide (LSALT) in patients with inflammation of the lungs and other organs such as the liver and kidneys; the ongoing clinical development of LSALT in future human trials and other indications outside of patients with COVID-19.
Forward-looking statements are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause our actual results to differ materially from those expressed or implied by the forward-looking statements contained in this press release. These risks and uncertainties include, but are not limited to, the risk that the results (either safety or efficacy, or both) obtained through the administration of LSALT in humans will not be similar to those obtained in preclinical or Phase I studies previously completed and phase II trials; or, that serious adverse effects resulting from the administration of LSALT are discovered leading to a suspension or cancellation of any development work with LSALT; and, the risk that competitors discover or introduce new treatments for organ inflammation that may be safer and/or more effective than LSALT.
Content of the article
We refer to potential investors in the “Risk Factors” section of our annual management and discussion and analysis dated January 28, 2022 available on SEDAR at www.sedar.com and on our website at www.archbiopartners.com for additional risks regarding the conduct of Arch Biopartners’ business and enterprise in general. The reader is cautioned to consider these and other risks and uncertainties carefully and not to place undue reliance on forward-looking statements. Forward-looking statements reflect current expectations about future events and speak only as of the date of this press release and represent management’s expectations as of that date.
The management of Arch Biopartners undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as required by the applicable legislation.
Neither the TSX Venture Exchange nor its regulation service provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
